collection
MENU ▼
Read by QxMD icon Read
search

LUNG

shared collection
216 papers 25 to 100 followers
https://www.readbyqxmd.com/read/27893277/lung-carcinoma-staging-update
#1
Sanja Dacic
CONTEXT: -The International Association for the Study of Lung Cancer Staging Committee has prospectively created an international lung cancer database that was used to address many lung cancer staging questions, such as tumor size, nodal status, and metastatic disease. The proposed changes for the upcoming 8th edition of the cancer staging manual were based on survival data and better prognostic stratification of patients with lung cancer. OBJECTIVES: -To review published recommendations for the revision of lung carcinoma TNM staging and to address potential challenges in pathologic staging...
November 28, 2016: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/27866095/continuing-egfr-inhibition-beyond-progression-in-advanced-non-small-cell-lung-cancer
#2
REVIEW
Timothy A Yap, Aislinn Macklin-Doherty, Sanjay Popat
The majority of patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) respond to first-line EGFR tyrosine kinase inhibitors (TKIs), but nearly all inevitably acquire resistance and develop disease progression. Conventional practice would be to switch treatments to second-line therapy. However, continuing TKIs beyond progression is becoming increasingly commonplace in patients with indolent, small volume asymptomatic growth, who may potentially continue to derive ongoing clinical benefit and to avoid a 'withdrawal tumour flare'...
November 17, 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/27865624/w-alk-into-the-next-stage
#3
REVIEW
Gouji Toyokawa, Takashi Seto, Mitsuhiro Takenoyama, Yukito Ichinose
In 2007, the rearrangement of anaplastic lymphoma kinase (ALK) was identified to be associated with the pathogenesis of a subset of patients with non-small-cell lung cancer (NSCLC). Surprisingly, approximately 4 years after the discovery of ALK rearrangement in lung cancer, the first-in-class ALK inhibitor (ALKi), crizotinib, was approved for metastatic ALK-rearranged NSCLC by the US Food and Drug Administration. Subsequently, next-generation ALKis, such as alectinib and ceritinib, have been developed, and some of them have been applied in the clinical setting...
October 26, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/27865876/interstitial-lung-disease-in-the-elderly
#4
Karen C Patterson, Rupal J Shah, Mary K Porteous, Jason D Christie, Carly D'Errico, Matthew Chadwick, Matthew Triano, Charuhas Deshpande, Milton D Rossman, Leslie A Litzky, Maryl E Kreider, Wallace T Miller
BACKGROUND: Despite the relationship of idiopathic pulmonary fibrosis (IPF) with advancing age, little is known about the epidemiology of interstitial lung diseases (ILD) in the elderly. Here we describe the diagnoses, clinical characteristics, and outcomes of patients who were elderly at the time of ILD diagnosis. METHODS: Among subjects from a prospective cohort study of ILD, elderly was defined as age > 70. Diagnoses were derived from a multi-disciplinary review...
November 16, 2016: Chest
https://www.readbyqxmd.com/read/27821794/understanding-mechanisms-of-resistance-in-the-epithelial-growth-factor-receptor-in-non-small-cell-lung-cancer-and-the-role-of-biopsy-at-progression
#5
REVIEW
Mark A Socinski, Liza C Villaruz, Jeffrey Ross
: : Molecular profiling and the discovery of drugs that target specific activating mutations have allowed the personalization of treatment for non-small cell lung cancer (NSCLC). The epithelial growth factor receptor (EGFR) is frequently overexpressed and/or aberrantly activated in different cancers, including NSCLC. The most common activating mutations of EGFR in NSCLC fall within the tyrosine kinase-binding domain. Three oral EGFR tyrosine kinase inhibitors (TKIs) have been approved by the U...
November 7, 2016: Oncologist
https://www.readbyqxmd.com/read/27826536/pembrolizumab-as-first-line-treatment-for-non-small-cell-lung-cancer-a-game-changer
#6
EDITORIAL
Wolfram C M Dempke, Klaus Fenchel
No abstract text is available yet for this article.
October 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27827466/what-is-better-reliable-mitosis-counting-or-ki67-mib1-staining
#7
EDITORIAL
Mark Kriegsmann, Arne Warth
No abstract text is available yet for this article.
October 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27827463/tumor-cell-proliferation-proliferative-index-and-mitotic-count-in-lung-cancer
#8
EDITORIAL
Lucian R Chirieac
No abstract text is available yet for this article.
October 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27827465/ki-67-expression-in-pulmonary-tumors
#9
EDITORIAL
Lucian R Chirieac
No abstract text is available yet for this article.
October 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27815523/histologist-s-original-opinion-compared-with-multidisciplinary-team-in-determining-diagnosis-in-interstitial-lung-disease
#10
LETTER
P S Burge, J Reynolds, S Trotter, G A Burge, G Walters
Guidelines recommend that multidisciplinary interstitial lung disease meeting (ILD MDT) decisions become the gold standard for diagnosis, replacing the histologist from this position, and identify this as requiring supportive evidence. We have compared diagnoses from lung biopsy material made by expert histologists with the subsequent consensus opinion from a properly constituted ILD MDT in 71 consecutive patients referred to a regional thoracic unit. MDT changed the original histological diagnoses in 30% (95% CI 19...
November 4, 2016: Thorax
https://www.readbyqxmd.com/read/27770511/epidermal-growth-factor-receptor-and-notch-signaling-in-non-small-cell-lung-cancer
#11
Joanna Pancewicz-Wojtkiewicz
Lung cancer is the most common reason of cancer deaths and about 85% of these are non-small-cell lung cancer. Currently, lung cancer therapy is mainly based on the tumor node metastasis (TNM) disease staging and tumor histological classification. Despite therapeutic innovations, the prognosis for lung cancer patients has not significantly changed in the last years. Therefore, a proper understanding of cell signaling pathways involved in cancer pathogenesis seems to be essential for improvement in cancer therapy field...
October 21, 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27053971/igg4-related-lung-disease-associated-with-usual-interstitial-pneumonia
#12
Frank Schneider, Kristen L Veraldi, Marc C Levesque, Thomas V Colby, Eunhee S Yi
We report a case of immunoglobulin(Ig)G4-related disease with the radiologic and histopathological manifestations resembling usual interstitial pneumonia (UIP). The patient was a 62-year-old man who presented with progressive dyspnea of insidious onset. High resolution computed tomography of the chest showed lower-lobe predominant peripheral reticulation and traction bronchiectasis but no honeycomb change. Microscopic examination of the surgical lung biopsy showed characteristic features of UIP including architectural distortion by fibrosis with peripheral and paraseptal accentuation, scattered fibroblast foci and microscopic honeycomb change...
2016: Open Rheumatology Journal
https://www.readbyqxmd.com/read/27766785/primary-pulmonary-angiosarcoma-three-case-reports-and-literature-review
#13
Yanhong Ren, Min Zhu, Yan Liu, Xiaoli Diao, Yuhui Zhang
Primary pulmonary angiosarcoma is a rare type of malignant vascular tumor with a very aggressive clinical course and a grim prognosis. To date, only a handful of cases have been reported in English literature. Its rarity and consequent low index of suspicion makes clinical diagnosis difficult. In this report we present three cases of primary pulmonary angiosarcoma with cough, hemoptysis, and progressive dyspnea to contribute to the sparse literature on this disease. A review is made of previous reports of primary pulmonary angiosarcomas, and the clinical characteristics, diagnosed method, treatment options, and prognosis of pulmonary angiosarcoma are also discussed...
September 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/27794501/targeting-met-in-lung-cancer-will-expectations-finally-be-met
#14
REVIEW
Alexander Drilon, Federico Cappuzzo, Sai-Hong Ignatius Ou, D Ross Camidge
The mesenchymal epithelial transition factor receptor (MET) is a potential therapeutic target in a number of cancers, including non-small cell lung cancer (NSCLC). In NSCLC, MET pathway activation is thought to occur via a diverse set of mechanisms that influence properties affecting cancer cell survival, growth, and invasiveness. Preclinical and clinical evidence suggest a role for MET activation as both a primary oncogenic driver in subsets of lung cancer, and as a secondary driver of acquired resistance to targeted therapy in other genomic subsets...
October 26, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27763791/challenges-of-frozen-section-in-thoracic-pathology-lepidic-lesions-limited-resections-and-margins
#15
Alain C Borczuk
CONTEXT: -The use of frozen section in thoracic pathology includes assessment of peripheral lung lesions with lepidic pattern, with greater emphasis on evaluating lung-sparing resections and margin assessment. OBJECTIVE: -To review pitfalls of frozen section in thoracic pathology; in this setting, reduction of false-positive and false-negative diagnosis in lesion identification and margin assessment is critical. DATA SOURCES: -PubMed search of frozen section lung pathology yielded specific references related to the use of frozen section in the identification of lepidic lesions and the clinical recommendation for margin distance...
October 20, 2016: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/27729263/utility-of-transbronchial-versus-surgical-lung-biopsy-in-the-diagnosis-of-suspected-fibrotic-interstitial-lung-disease
#16
Jamie S Sheth, John A Belperio, Michael C Fishbein, Ella A Kazerooni, Amir Lagstein, Susan Murray, Jeff L Myers, Richard H Simon, Thomas H Sisson, Baskaran Sundaram, Eric S White, Meng Xia, David Zisman, Kevin R Flaherty
BACKGROUND: Surgical lung biopsy (SLB) is invasive and not possible in all patients with undiagnosed interstitial lung diseases (ILD). We hypothesized that transbronchial biopsy (TBB) findings combined with clinical and high resolution computed tomography (HRCT) data leads to a confident diagnosis congruent to SLB, and therefore avoids the need for SLB in some patients. METHODS: We evaluated 33 patients being evaluated for suspected ILD who underwent HRCT, TBB and SLB...
October 8, 2016: Chest
https://www.readbyqxmd.com/read/27769776/immunotherapy-of-lung-malignancies-from-gene-sequencing-to-novel-therapies
#17
J Chee, B W S R Robinson, R A Holt, J Creaney
Harnessing the immune system to fight cancer is an exciting advancement in lung cancer therapy. Anti-tumor immunity can be augmented by checkpoint blockade therapy, which removes the inhibition/brakes imposed on the immune system by the tumor. Checkpoint blockade therapy with anti-PD1/anti-PDL1 antibodies causes tumor regression in around 25% of lung cancer patients. In another approach, the immune system is forced or accelerated to attack the tumour, via augmentation of the anti-tumour response against mutations carried by each lung tumour...
October 18, 2016: Chest
https://www.readbyqxmd.com/read/27780786/the-8-th-edition-lung-cancer-stage-classification
#18
REVIEW
Frank C Detterbeck, Daniel J Boffa, Anthony W Kim, Lynn T Tanoue
Stage classification provides a nomenclature about the anatomic extent of a cancer; a consistent language provides the ability to communicate about a specific patient and about cohorts of patients in clinical studies. This paper summarizes the 8(th) edition of lung cancer stage classification, which is the worldwide standard as of January 1, 2017. This revision is based on a large global database, a sophisticated analysis, extensive internal validation as well as multiple assessments confirming generalizability...
October 22, 2016: Chest
https://www.readbyqxmd.com/read/27779369/analysis-of-clinical-characteristics-and-prognosis-of-patients-with-anaplastic-lymphoma-kinase-positive-and-surgically-resected-lung-adenocarcinoma
#19
Hong Tao, Yiran Cai, Liang Shi, Junfang Tang, Zhidong Liu, Zitong Wang, Lianqi Bai, Zhe Liu
BACKGROUND: Recent research into lung cancer-related driver genes has identified a distinctive molecular subtype of non-small cell lung cancer (NSCLC) - anaplastic lymphoma kinase (ALK)-positive NSCLC. We evaluated the clinical features and survival rates of ALK-positive lung adenocarcinoma patients who had undergone surgery but had not received ALK inhibitor therapy, along with the characteristics of patients with distant metastases. METHODS: Clinical data of 40 patients with ALK-positive, postsurgical lung adenocarcinoma were retrospectively analyzed...
October 24, 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/27766772/epidermal-growth-factor-receptor-egfr-tyrosine-kinase-inhibitors-combined-with-chemotherapy-in-first-line-treatment-in-an-advanced-non-small-cell-lung-cancer-patient-with-egfr-sensitive-mutation
#20
Aimi Huang, Rong Li, Jikai Zhao, Xiaofei Wang, Bo Jin, Yanjie Niu, Jie Zhang, Liyan Jiang, Baohui Han
This article demonstrates a case of a lung adenocarcinoma patient in stage IV harboring an epidermal growth factor receptor (EGFR) 19 exon deletion mutation treated with 500 mg/m(2) pemetrexed and 75 mg/m(2) cisplatin on day 1, sequenced with 250 mg gefitinib on prescription on days 4-28 for six cycles as first-line, then by gefitinib combined with pemetrexed as maintenance therapy. The patient achieved a partial response. Performance status increased from grade 2 to 1. The progression-free survival period was 17 months...
September 2016: Thoracic Cancer
label_collection
label_collection
6334
1
2
2016-10-28 08:28:26
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"